iData Insights

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 04, 2016 14:58 IST

This report provides comprehensive information on the therapeutic development for Cervical Intraepithelial Neoplasia (CIN), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cervical Intraepithelial Neoplasia (CIN) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cervical Intraepithelial Neoplasia (CIN) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cervical Intraepithelial Neoplasia (CIN) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179123/cervical-intraepithelial-neoplasia-cin-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179123/cervical-intraepithelial-neoplasia-cin-pipeline-review-h2-2015

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cervical Intraepithelial Neoplasia (CIN) Overview 6

Therapeutics Development 7

Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Overview 7

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Development by Companies 8

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Products Glance 9

Clinical Stage Products 9

Cervical Intraepithelial Neoplasia (CIN) - Products under Development by Companies 10

Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development 11

CEL-SCI Corporation 11

Helix BioPharma Corp. 12

Inovio Pharmaceuticals, Inc. 13

PDS Biotechnology Corporation 14

Vaccibody AS 15

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Drug Profiles 25

GLBL-101c - Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

interferon alpha-2b (recombinant) - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Leukocyte Interleukin - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

PDS-0101A - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

VB-1016 - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

VGX-3100 - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Cervical Intraepithelial Neoplasia (CIN) - Recent Pipeline Updates 36

Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects 52

Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products 53

Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones 54

Featured News & Press Releases 54

Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet 54

Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 55

Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 56

Feb 11, 2014: PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune Cancer Immunotherapy Platform in a Phase 1 Clinical Trial 57

Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study 58

May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer 59

Nov 11, 2011: FDA Removes Clinical Hold For Helix's Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application 60

Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines 60

Oct 05, 2011: Inovio's Synthetic Vaccine for Cancer Recognized As Most Promising Research at Global Vaccine Congress 61

Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 62

Appendix 64

Methodology 64

Coverage 64

Secondary Research 64

Primary Research 64

Expert Panel Validation 64

Contact Us 64

Disclaimer 65" width="80" height="40" />Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Cervical Intraepithelial Neoplasia (CIN) Overview 6

Therapeutics Development 7

Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Overview 7

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Development by Companies 8

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Products Glance 9

Clinical Stage Products 9

Cervical Intraepithelial Neoplasia (CIN) - Products under Development by Companies 10

Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development 11

CEL-SCI Corporation 11

Helix BioPharma Corp. 12

Inovio Pharmaceuticals, Inc. 13

PDS Biotechnology Corporation 14

Vaccibody AS 15

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Drug Profiles 25

GLBL-101c - Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

interferon alpha-2b (recombinant) - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Leukocyte Interleukin - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

PDS-0101A - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

VB-1016 - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

VGX-3100 - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Read More http://www.idatainsights.com/reports-landing-page.php?id=179123/cervical-intraepithelial-neoplasia-cin-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.